Healthcare · NYSE/NASDAQ: PODD
INSULET CORP
Medical Devices
Market Cap $10.26B
Verdict: High
Quality Scores
Multi-Bagger
85/100
Compounder Quality
87/100
Management Credibility
92/100
Governance
88/100
Cash Flow Quality
95/100
AI Summary
Insulet Corporation (PODD) has transitioned from a high-growth medical device speculative play to a profitable compounding machine over the last decade. Revenue soared from $366.99M in 2016 to $2.71B in 2025, reflecting the massive adoption of its Omnipod insulin delivery system. The company achieved a critical profitability inflection point around 2018-2023, with Net Income surging from marginal figures to $247.10M recently. While debt levels were historically high to fund R&D and manufacturing scale, the current balance sheet shows significant deleveraging and equity growth. Insulet now…
Top Opportunities
- Consistent 20%+ revenue CAGR over 10 years
- Omnipod 5 market-leading automated insulin delivery
- Subscription-based recurring revenue model
Top Risks
- High historical valuation multiples
- Heavy R&D expenditure required to stay competitive
- Significant competition from Tandem and Medtronic
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.